TerminatedPhase 2NCT04129151
Palbociclib + Ganitumab In Ewing Sarcoma
Studying Extraskeletal Ewing sarcoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Dana-Farber Cancer Institute
- Principal Investigator
- David Shulman, MDDana-Farber Cancer Institute
- Intervention
- Palbociclib(drug)
- Enrollment
- 10 enrolled
- Eligibility
- 12-50 years · All sexes
- Timeline
- 2019 – 2022
Study locations (3)
- Massachusetts General Hospital, Boston, Massachusetts, United States
- Boston Children's Hospital, Boston, Massachusetts, United States
- Dana Farber Cancer Institute, Boston, Massachusetts, United States
Collaborators
1 Million 4 Anna Foundation · Carson Sarcoma Foundation · Teaming up to Fight Childhood Cancer · ChemoWarrior: the eli sidler foundation · i-ROK Foundation · Rutledge Cancer Foundation · Alan B. Slifka Foundation
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04129151 on ClinicalTrials.gov